GenSight Biologics S.A.
SIGHT
Rank in Stocks
#27626
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on... GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
Share Price
$0.08686381
Last synced: 2026-11-09
Market Cap
$14.16M
Change (1 day)
12.60%
Change (1 year)
-37.76%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade GenSight Biologics S.A. (SIGHT)
Category
Healthcare
Operating Margin for GenSight Biologics S.A. (SIGHT)
Operating Margin as of November 2026 TTM: 1,526.14%
According to GenSight Biologics S.A.'s latest financial reports, its current operating margin (TTM) is 1,526.14%. At the end of 2025 the company had an operating margin of -1,170,500.00%.
Operating Margin history for GenSight Biologics S.A. from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 1,526.14% | -100.13% |
| 2025 | -1,170,500.00% | 194,206.11% |
| 2024 | -602.40% | -74.30% |
| 2023 | -2,343.80% | 117.41% |
| 2022 | -1,078.04% | 102.22% |
| 2021 | -533.09% | -6.06% |
| 2020 | -567.46% | -86.89% |
| 2019 | -4,328.29% | 469.25% |
| 2018 | -760.35% | 17.33% |
| 2017 | -648.03% | -11.68% |
| 2016 | -733.71% | 91.20% |
| 2015 | -383.74% | -37.25% |
| 2014 | -611.52% | 95.72% |
| 2013 | -312.44% | 0.00% |
| 2012 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -99.97% |
US
|
|
| -149.01% | -100.10% |
US
|
|
| 25.57% | -99.98% |
AU
|
|
| 31.23% | -99.98% |
BE
|
|
| 29.35% | -99.98% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about GenSight Biologics S.A.'s operating margin
What is GenSight Biologics S.A.'s operating margin?
GenSight Biologics S.A.'s operating margin is 1,526.14%, as of Nov 2026.
What was GenSight Biologics S.A.'s operating margin in 2025?
In 2025, GenSight Biologics S.A.'s operating margin was -1,170,500.00%, compared with -602.40% in 2024.
How has GenSight Biologics S.A.'s operating margin changed since 2020?
From 2020 to 2025, GenSight Biologics S.A.'s operating margin was highest in 2021 (-533.09%) and lowest in 2025 (-1,170,500.00%).
How does GenSight Biologics S.A.'s operating margin compare with similar companies?
GenSight Biologics S.A.'s operating margin (1,526.14%) is higher than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.